RenovoRx, Imugene Partner to Deliver Oncolytic Virus Therapy
RenovoRx, Inc., a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd., a clinical-stage immuno-oncology company, entered into a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.